Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lenalidomide Market

Lenalidomide Market Trends

Report ID: GMI8286
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Lenalidomide Market Trends

The landscape of blood cancer treatment is continually evolving, driven by advancements in innovative therapies. Lenalidomide plays a pivotal role, particularly as a complement to emerging treatments and in enhancing treatment efficacy.

The market is propelled by the development of groundbreaking treatments for blood cancer. These advancements often emphasize combination therapies, where lenalidomide's role is to augment effectiveness or synergize with newer agents. As these novel treatments lead to improved patient outcomes and prolonged survival rates, the demand for lenalidomide surges, whether as a component of initial treatment strategies or subsequent lines of therapy.
According to an article published by the Leukemia & Lymphoma Society in 2023, the recent FDA approvals of talquetamab-tgvs (Talve) and elranatamab (Elrexfio) for treating refractory or relapsed multiple myeloma mark a significant milestone in immunotherapy.
These bispecific antibodies represent cutting-edge research-led advancements and are the first of their kind tailored specifically for multiple myeloma. The introduction of such novel treatment options underscores the dynamic evolution of multiple myeloma therapies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Lenalidomide industry size was worth USD 18 billion in 2023 and is set to expand at 5.1% CAGR from 2024-2032 propelled by the escalating prevalence of multiple myeloma worldwide and continuous advancements spurred by research endeavors.

The 10mg capsules segment generated USD 6.1 billion in revenue in 2023 and is projected to record substantial growth through 2032 as these capsules serve as a cornerstone in medical treatment regimens for offering patients a reliable and standardized dosage.

North America lenalidomide market accounted for a sizeable revenue share in 2023 and is expected to expand at a significant growth rate through 2032 owing to the heightened incidence rate of these diseases in comparison to other regions globally.

Some of the major lenalidomide firms are Accord Healthcare, Cipla, Deva Pharma, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals, Hetero, Lupin Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Viatris Inc., among others.